Valneva SE (VIE:VLA)
Austria flag Austria · Delayed Price · Currency is EUR
3.096
-0.036 (-1.15%)
Last updated: Apr 24, 2025

Valneva SE Company Description

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate which is in Phase III clinical trial against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a Phase I vaccine candidate targeting the Zika virus (ZIKV), a mosquito-borne viral disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally.

Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine.

The company was founded in 1998 and is based in Saint-Herblain, France.

Valneva SE
Valneva SE logo
Country France
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 713
CEO Thomas Lingelbach

Contact Details

Address:
6 rue Alain Bombard
Saint-Herblain, 44800
France
Phone 33 2 28 07 37 10
Website valneva.com

Stock Details

Ticker Symbol VLA
Exchange Vienna Stock Exchange
Fiscal Year January - December
Reporting Currency EUR
ISIN Number FR0004056851
SIC Code 2836

Key Executives

Name Position
Thomas Lingelbach President, Chief Executive Officer and Director
Peter Buhler Chief Financial Officer
Franck Grimaud MBA Chief Business Officer
Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer
Dipal Patel Chief Commercial Officer
Vincent Dequenne Chief Operating Officer
Dr. Hanneke Schuitemaker Ph.D. Chief Scientific Officer
Joshua Drumm Ph.D. Vice President of Investor Relations
Kendra Wergin General Counsel and Corporate Secretary
Laetitia Bachelot-Fontaine Vice President of Global Communications and European Investor Relations